These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 36282074

  • 1. Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department: The SPECTRUM Study.
    Bager JE, Martín A, Carbajosa Dalmau J, Simon A, Merino JL, Ritz B, Hartikainen JEK.
    Cardiology; 2022; 147(5-6):566-577. PubMed ID: 36282074
    [Abstract] [Full Text] [Related]

  • 2. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA.
    Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
    [Abstract] [Full Text] [Related]

  • 3. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S, Hartikainen J, Ritz B, Juhlin T, Carbajosa-Dalmau J, Domanovits H.
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
    [Abstract] [Full Text] [Related]

  • 4. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P, Gilligan P, Mahon P, Sheahan R.
    Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN, Mangal B.
    BMC Cardiovasc Disord; 2016 May 28; 16():113. PubMed ID: 27233239
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 28; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness and Safety Profiles of Vernakalant for Cardioversion of Acute-onset Atrial Fibrillation: A Systematic Review and Meta-analysis.
    Yu C, Li J, Zhao C, Guan Y, Wu D, Sun B, Wang X.
    Clin Ther; 2023 Mar 28; 45(3):218-231. PubMed ID: 36828756
    [Abstract] [Full Text] [Related]

  • 8. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter.
    Stiell IG, Clement CM, Perry JJ, Vaillancourt C, Symington C, Dickinson G, Birnie D, Green MS.
    CJEM; 2010 May 28; 12(3):181-91. PubMed ID: 20522282
    [Abstract] [Full Text] [Related]

  • 9. Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation.
    Ma W, Guo X, Wang Q, Sun G, Wang J.
    J Cardiovasc Pharmacol; 2020 Jul 28; 76(1):32-41. PubMed ID: 32251022
    [Abstract] [Full Text] [Related]

  • 10. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
    Pohjantähti-Maaroos H, Hyppölä H, Lekkala M, Sinisalo E, Heikkola A, Hartikainen J.
    Eur Heart J Acute Cardiovasc Care; 2019 Mar 28; 8(2):114-120. PubMed ID: 28849946
    [Abstract] [Full Text] [Related]

  • 11. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
    Mochalina N, Juhlin T, Öhlin B, Carlson J, Holmqvist F, Platonov PG.
    Ann Noninvasive Electrocardiol; 2015 Mar 28; 20(2):140-7. PubMed ID: 25040826
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
    Akel T, Lafferty J.
    Ann Noninvasive Electrocardiol; 2018 May 28; 23(3):e12508. PubMed ID: 29105209
    [Abstract] [Full Text] [Related]

  • 13. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
    Simon A, Niederdoeckl J, Skyllouriotis E, Schuetz N, Herkner H, Weiser C, Laggner AN, Domanovits H, Spiel AO.
    Europace; 2017 Feb 01; 19(2):233-240. PubMed ID: 28175295
    [Abstract] [Full Text] [Related]

  • 14. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.
    Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G, AVRO Investigators.
    J Am Coll Cardiol; 2011 Jan 18; 57(3):313-21. PubMed ID: 21232669
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Intravenous Vernakalant in Rapid Cardioversion of Recent Onset Atrial Fibrillation: A Retrospective Single-Centre Study.
    Hoteit A, Moumneh MB, Nahlawi A, Hebbo E, Abdulhai F, Abi-Saleh B, Khoury M, Refaat M.
    Cureus; 2024 Apr 18; 16(4):e58616. PubMed ID: 38770450
    [Abstract] [Full Text] [Related]

  • 16. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter.
    Stiell IG, Clement CM, Symington C, Perry JJ, Vaillancourt C, Wells GA.
    Acad Emerg Med; 2007 Dec 18; 14(12):1158-64. PubMed ID: 18045891
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN, Bhirangi K, Juul-Moller S, Rustige J.
    J Cardiovasc Pharmacol; 2017 Feb 18; 69(2):86-92. PubMed ID: 27828791
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y, Dobrev D.
    Vasc Health Risk Manag; 2013 Feb 18; 9():165-75. PubMed ID: 23637539
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 20. Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.
    Farkowski MM, Maciag A, Zurawska M, Kowalik I, Szwed H, Pytkowski M.
    Cardiovasc Ther; 2018 Dec 01; 36(6):e12469. PubMed ID: 30281920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.